Kleihauer A, Grigoleit U, Hebart H, Moris A, Brossart P, Muhm A, Stevanovic S, Rammensee H G, Sinzger C, Riegler S, Jahn G, Kanz L, Einsele H
Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Germany.
Br J Haematol. 2001 Apr;113(1):231-9. doi: 10.1046/j.1365-2141.2001.02681.x.
Adoptive transfer of donor-derived human cytomegalovirus (HCMV)-specific T-cell clones can restore protective immunity after stem cell transplantation. Ex vivo induction of HCMV-specific T cells using HCMV-infected fibroblasts as stimulator cells confines this approach to HCMV-seropositive donors and requires the presence of infectious virus during the stimulation procedure. In this study, we describe a potential alternative strategy to generate HCMV-specific T cells ex vivo for adoptive immunotherapy. Generation of HCMV-specific cytotoxic T lymphocytes (CTLs) ex vivo was investigated using peptide-pulsed dendritic cells as antigen-presenting cells. HCMV-specific T cells were generated and sufficiently expanded for adoptive immunotherapy in 6 out of 14 HCMV-seropositive and 2 out of 11 HCMV-seronegative donors. The CTLs recognized HCMV-infected autologous fibroblasts. No lysis was observed with either non-infected autologous or HLA-mismatched infected fibroblasts. Staining with tetrameric HLA/peptide complexes revealed significant enrichment for peptide-specific T cells of up to 28% and > 90% of CD8(+) T cells after three and five specific stimulations respectively. In addition, the expansion rates indicated that ex vivo generation of > 1 x 10(9) HCMV-specific T cells was possible after 6--7 weeks when cultures were initiated with 1--5 x 10(6) responder cells. Thus, the approach with peptide-pulsed DCs to generate HCMV-specific CTLs is feasible for clinical application after allogeneic stem cell transplantation.
供体来源的人巨细胞病毒(HCMV)特异性T细胞克隆的过继性转移可在干细胞移植后恢复保护性免疫。使用HCMV感染的成纤维细胞作为刺激细胞在体外诱导HCMV特异性T细胞,这使得该方法仅限于HCMV血清阳性供体,并且在刺激过程中需要有感染性病毒存在。在本研究中,我们描述了一种在体外产生用于过继性免疫治疗的HCMV特异性T细胞的潜在替代策略。使用肽脉冲树突状细胞作为抗原呈递细胞,研究了在体外产生HCMV特异性细胞毒性T淋巴细胞(CTL)。在14名HCMV血清阳性供体中的6名以及11名HCMV血清阴性供体中的2名中,成功产生并充分扩增了用于过继性免疫治疗的HCMV特异性T细胞。这些CTL识别HCMV感染的自体成纤维细胞。未感染的自体成纤维细胞或HLA不匹配的感染成纤维细胞均未观察到裂解现象。用四聚体HLA/肽复合物染色显示,分别在三次和五次特异性刺激后,肽特异性T细胞显著富集,分别高达28%和>90%的CD8(+)T细胞。此外,扩增率表明,当用1--5×10(6)个反应细胞开始培养时,在6-7周后体外产生>1×10(9)个HCMV特异性T细胞是可能的。因此,用肽脉冲DC产生HCMV特异性CTL的方法在异基因干细胞移植后用于临床应用是可行的。